NCT03022955

Brief Summary

This is a randomized, controlled, 2x2 cross-over study to assess the effects of cocoa solids on gastrointestinal transit, post-prandial sensation and well-being. Additionally functional brain imaging will be applied to identify regions of brain that are activated or inactivated by cocoa ingestion. Healthy subjects will be recruited and randomized to receive either dark chocolate (70% cocoa solids) or white chocolate (0% cocoa solids) in addition to their normal diet in randomized order. Reference standard methodology will be applied to measure gastric emptying, oro-caecal and colonic transit time. Dark and white chocolate (100g, \~500kcal, \~50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity using FDG-Positron Emission Tomography. Additionally colonic transit will be assessed based on the number and distribution of radio-opaque markers in the colon. On the fourth day gastric emptying and oro-caecal transit time will be assessed by scintigraphy after ingestion of a dark or white chocolate mousse test meal (both 150g, \~500kcal, \~50% fat). During both interventional studies pre- and post-prandial satiety and dyspeptic symptoms, well-being and mood will be recorded. Additionally, validated questionnaires will assess digestive comfort and well-bring at the end of each study day. These results will deliver comprehensive information about the effects of cocoa on gastrointestinal transit and sensation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

January 10, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 18, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2017

Completed
Last Updated

February 12, 2018

Status Verified

February 1, 2018

Enrollment Period

5 months

First QC Date

January 10, 2017

Last Update Submit

February 9, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Gastric emptying half time

    assessed by scintigraphy

    Baseline until 2 hours postingestion

Secondary Outcomes (4)

  • Oro-caecal transit time (OCTT)

    Baseline until 3 hours postingestion

  • Colonic transit time

    Baseline until 3 days after ingestion

  • Post-prandial satiety

    changes from baseline to three hours after treatment

  • Gastrointestinal well-being

    changes from baseline to three hours after treatment

Study Arms (4)

Dark chocolate: FDG-PET

ACTIVE COMPARATOR

100 g dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)

Dietary Supplement: Dark chocolate bar

Dark chocolate: Physiological Measurement

ACTIVE COMPARATOR

150 g dark chocolate mousse (\~500kcal, \~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.

Dietary Supplement: Dark chocolate mousse

White chocolate: FDG-PET

PLACEBO COMPARATOR

100 g white chocolate bar (0% cocoa solids (\~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.

Dietary Supplement: White chocolate bar

White chocolate: Physiological Measurement

PLACEBO COMPARATOR

150 g white chocolate mousse (\~500kcal, \~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.

Dietary Supplement: White chocolate mousse

Interventions

Dark chocolate barDIETARY_SUPPLEMENT

Dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.

Dark chocolate: FDG-PET
Dark chocolate mousseDIETARY_SUPPLEMENT

Dark chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.

Dark chocolate: Physiological Measurement
White chocolate barDIETARY_SUPPLEMENT

White chocolate bar (0% cocoa solids (\~500kcal, 50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.

White chocolate: FDG-PET
White chocolate mousseDIETARY_SUPPLEMENT

White chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.

White chocolate: Physiological Measurement

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy volunteers (men and women)
  • aged 18-65 years
  • body mass index 18-30kg/m2.

You may not qualify if:

  • special dietary requirements incompatible with dietary intervention (food allergies or intolerances)
  • clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) that preclude intake of test meals
  • participation in another study with investigational drug within the 30 days preceding and during the present study (purely diagnostic studies are acceptable)
  • individuals unwilling to provide written informed consent
  • inability to follow the procedures of the study, e.g. due to language problems (all study documents in English)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St Claraspital

Basel, 4016, Switzerland

Location

MeSH Terms

Conditions

Digestive System Diseases

Study Officials

  • Mark Fox, Prof. Dr.

    St. Claraspital Basel, Abdominal Center: Gastroenterology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 10, 2017

First Posted

January 18, 2017

Study Start

January 1, 2017

Primary Completion

June 1, 2017

Study Completion

June 1, 2017

Last Updated

February 12, 2018

Record last verified: 2018-02

Locations